Buffett’s $1.6B UNH Shockwave: Join the Play or Sit This One Out?

$UnitedHealth(UNH)$ Warren Buffett’s Berkshire Hathaway dropped a bombshell with its Q2 2025 13F filing today, August 15, 2025, unveiling a bold new stake in UnitedHealth Group (UNH). The investment giant snapped up 5.039 million shares of the U.S. health insurance titan for approximately $1.6 billion, with an average purchase price of $314 per share. By quarter’s end, the position was valued at $1.57 billion, securing its spot as the 18th largest holding in Berkshire’s $300 billion portfolio, trailing Amazon and Constellation Brands (STZ). With the S&P 500 at 6,466.58, Nasdaq at 21,713.14, and Bitcoin surging to $124,002, the market pulses with optimism, though tariffs (30% on EU/Mexico, 35% on Canada) and oil at $75/barrel cast shadows. Is this Buffett’s signal to buy UNH at $300, or a risky move in a troubled sector? This deep dive explores the bet, market reactions, and strategies to navigate this high-stakes opportunity.

The Buffett Bet: Why UnitedHealth?

Buffett’s move into UnitedHealth signals a strategic pivot:

Scale of Investment: The $1.6 billion purchase, executed at $314 per share, reflects confidence in a company with a $216 billion market cap, despite a 46% YTD drop to $250.74 as of August 8, 2025.
Historical Context: After exiting UnitedHealth in 2010 with 1.18 million shares, Buffett’s return suggests a reevaluation, possibly driven by deputies Todd Combs or Ted Weschler, given his 95th birthday this month and impending CEO transition to Greg Abel.
Company Challenges: UnitedHealth grapples with soaring medical costs, a Justice Department probe into Medicare billing, a cyberattack, and the exit of CEO Andrew Witty, yet its $410 billion revenue and $22 billion profit over 12 months hint at resilience.
Portfolio Fit: Ranking 18th behind Amazon ($3.8 billion stake) and STZ ($1.58 billion), this 0.52% portfolio allocation underscores a calculated entry into healthcare, a sector Buffett once dubbed a “tapeworm” on the economy.

The move defies UnitedHealth’s recent 22% stock plunge from $585.04 to $454.11 in April 2025, suggesting Buffett sees value where others see risk.

Market Reaction: A Mixed Bag

The filing sparked immediate ripples:

Stock Surge: UNH jumped 7% in after-hours trading to $268, with support at $250 and resistance at $280, reflecting investor enthusiasm for Buffett’s backing.
Sector Impact: Health insurers like CVS Health rose 2.5% to $58.20, while peers Humana and Cigna gained 1.8% and 1.5% to $345.60 and $320.10, respectively, signaling a sector lift.
Broader Market: The S&P 500’s 6,466.58 and Nasdaq’s 21,713.14 held steady, with a 4.05-to-1 advancer-decliner ratio, though tariff fears could cap gains.
Sentiment Shift: Posts found on X show a split—some hail it as a “Buffett bargain,” others question the timing amid UnitedHealth’s woes, hinting at polarized views.

The VIX at 14.49 suggests controlled volatility, but a potential 5-10% market dip to 6,150-6,200 could test this rally if trade tensions flare.

Is $300 a Buy? The Pros and Cons

Buffett’s $314 entry price offers a benchmark:

Bull Case: At $250.74, UNH trades 20% below Buffett’s cost, with a 13x trailing earnings ratio and 3.58% dividend yield, appealing to value investors. Analysts see a $420-$470 target by 2026, per recent posts, if Medicare Advantage stabilizes.
Bear Case: A 46% YTD drop reflects real issues—$5 billion in extra costs, regulatory scrutiny, and a lowered 2025 profit forecast. A further 10-15% slide to $210-$225 is possible if probes intensify.
Technical View: RSI at 38 nears oversold (below 30), with support at $240-$245 and resistance at $280-$300. A break above $300 could target $320-$340, but a drop below $240 risks $200.
Buffett’s Lens: His 2018 healthcare venture with Bezos and Dimon, though shuttered, shows interest in reform. This stake might bet on UnitedHealth’s dominant 29% Medicare Advantage share and $84 trillion in U.S. senior wealth.

Buying at $300 could yield 20-30% upside if fundamentals improve, but a dip to $240 might offer a safer entry.

Trading Strategies: Ride or Hedge Buffett’s Play

Short-Term Plays

Buy on Dip: Enter at $260-$270, target $300-$310, stop at $250. A 15-19% gain if Buffett’s bet boosts sentiment.
Scalp Rally: Buy at $268-$270, sell at $280-$285, stop at $260. A 4-6% gain on momentum.
Options Play: Sell $280 calls (August expiry) for 100-150% premium decay, or buy $260 puts as a hedge.
Breakout Target: Buy at $280-$290, target $320, stop at $270. A 10-14% upside if resistance breaks.

Long-Term Investments

Hold UNH: Buy at $260-$270, target $350-$400 by 2026, for 30-53% upside if healthcare stabilizes. Stop at $240.
Diversify with CVS: Buy at $58-$60, target $70-$75, for 17-25% upside with pharmacy synergy. Stop at $55.
Tech Play: Buy Amazon (AMZN) at $185-$190, target $220-$240, for 16-26% upside with portfolio tie-in. Stop at $180.
Defensive Pick: Buy Coca-Cola (KO) at $68-$70, target $75-$80, for 10-14% upside with stability. Stop at $65.

Hedge Strategies

VIXY ETF: Buy at $14, target $17, stop at $12, to hedge volatility or tariff risks.
SPY Puts: Use puts at $646 for a 5-10% market drop if sentiment sours.
Gold (GLD): Buy at $200, target $220, stop at $190, as a safe-haven play.

My Trading Plan: Following Buffett’s Lead

I’m intrigued by Buffett’s UNH bet and see value in the dip. I’ll buy at $260-$270, targeting $300-$310, with a $250 stop, banking on a sentiment-driven rebound. I’ll add $CVS Health(CVS)$ at $58-$60, aiming for $65, with a $55 stop, and $Amazon.com(AMZN)$ at $185-$190, targeting $200, with a $180 stop. For stability, I’ll pick KO at $68-$70, targeting $73, with a $65 stop. I’m hedging with $ProShares VIX Short-Term Futures ETF(VIXY)$ at $14, targeting $16, and holding 20% cash for a tariff-driven pullback or regulatory news. I’ll monitor Medicare Advantage trends and insider moves.

Key Metrics

The Bigger Picture

Buffett’s $1.6 billion plunge into UnitedHealth at $314, revealed today, lifts UNH 7% to $268 amid a 46% YTD drop, with the S&P 500 at 6,466.58 and Bitcoin at $124,002 fueling optimism. Yet, regulatory probes and a potential 10-15% dip to $210-$225 threaten stability. At $268, it’s 15% below Buffett’s entry, offering a buy at $300 for 20-30% upside if Medicare Advantage recovers. Investors should buy dips, hedge with VIXY or GLD, and watch tariff and DOJ developments. This could be your Buffett-inspired edge—move decisively.

Will you follow Buffett into UNH at $300? Share your take below! 🎁

📢 Like, repost, and follow for daily updates on market trends and stock insights.

📝 Disclaimer: This post is for informational purposes only and does not constitute financial advice. Always conduct your own research before making investment decisions.

📌@Daily_Discussion @Tiger_comments @TigerStars @TigerEvents @TigerWire

UNH Breakout: Next Target $400?

UnitedHealth continues to jump after the health insurer reaffirmed its full-year 2025 earnings outlook. The company said it continues to expect adjusted earnings of at least $16.00 per share with revenue in the range of $445.5 billion to $448.0 billion. Wall Street currently forecasts earnings of $16.24 per share on revenue near $448.2 billion. ----------- After breaking the key resistance level of $320, is UNH hitting the short term peak? Have you jumped on the wagon with Buffett?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.